BOULDER, Colo., Sept. 26, 2016
BOULDER, Colo., Sept. 26, 2016 /PRNewswire/ -- Accera, Inc., a clinical-stage biotechnology company focused on product development for Alzheimer's disease, today announced that the company will present at the following upcoming investor conferences:
Accera, Inc. is a clinical-stage biotechnology company based in Boulder, Colo., that is developing therapies for central nervous system disorders. The company's proprietary scientific platform addresses unmet medical needs in brain health, including Alzheimer's disease. Accera is focused on the clinical development of drugs with innovative mechanisms of actions. The company's management team includes globally recognized specialists in central nervous system diseases and drug development, who together leverage the latest scientific knowledge and understanding of neurological disorders. Accera's lead product candidate is AC-1204, a ketosis-inducing compound in a Phase 3 clinical study in patients with mild to moderate Alzheimer's disease. For more information, visit www.accerapharma.com.
Follow Accera on Twitter at twitter.com/accerainc.
Accera Media Contacts:
Russo Partners LLC
Todd Davenport, Ph.D.
(858) 717-2310 Mobile
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/accera-to-present-at-upcoming-healthcare-and-investor-conferences-300333723.html
SOURCE Accera, Inc.PR Newswire
Last updated on: 26/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.